Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Oculis has raised €237M across 5 funding rounds from 14 investors, most recently a Debt round in Aug 2025. Based in Lausanne, Switzerland; founded 2003; active in Healthtech. The company has exited (2022). Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-08-13 | Debt | €106M | BlackRock | View deal → |
| 2024-04-12 | Other | €55M | Existing investors |
| View deal → |
| 2023-02-06 | Other | €14M | — | View deal → |
| 2021-05-05 | Series C | €47M | Bay City Capital,Brunnur Ventures,BVCF Management,Earlybird,Hyfinity Investments,Nan Fung Life Sciences+6 more | View deal → |
| 2019-01-01 | Series B | €14M | Tekla Capital Management | View deal → |
